Loading clinical trials...
Loading clinical trials...
Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 and Increased Inflammatory Markers: a Phase III Randomized Clinical Trial (COVID-19 Coalition Brazil VI) (TOCIBRAS)
Conditions
Interventions
Tocilizumab
Locations
7
Brazil
HCOR -Hospital do Coracao
São Paulo, São Paulo, Brazil
UNIFESP
São Paulo, São Paulo, Brazil
HAOC - Hospital Alemao Oswaldo Cruz
São Paulo, Brazil
Beneficência Portuguesa de Sao Paulo
São Paulo, Brazil
HAOC - Hospital Alemao Oswaldo Cruz - unidade Vergueiro
São Paulo, Brazil
HIAE - Hospital Israelita Albert Einstein
São Paulo, Brazil
Start Date
May 8, 2020
Primary Completion Date
July 8, 2020
Completion Date
July 21, 2020
Last Updated
August 26, 2020
NCT06721949
NCT07221162
NCT06082518
NCT06631287
NCT06679140
NCT06417762
Lead Sponsor
Beneficência Portuguesa de São Paulo
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions